Solid Biosciences (NASDAQ:SLDB) Price Target Raised to $12.00 at JPMorgan Chase & Co.

Solid Biosciences (NASDAQ:SLDB) had its price objective lifted by JPMorgan Chase & Co. from $11.00 to $12.00 in a research report released on Wednesday morning,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities research analysts have also recently issued reports on SLDB. Chardan Capital reaffirmed a “buy” rating and set a $15.00 price objective on shares of Solid Biosciences in a research report on Friday, March 20th. Citigroup reissued a “market outperform” rating on shares of Solid Biosciences in a report on Wednesday, December 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Solid Biosciences in a research note on Thursday, January 22nd. Guggenheim started coverage on Solid Biosciences in a report on Friday, March 20th. They set a “buy” rating and a $26.00 price target for the company. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $19.00 price objective on shares of Solid Biosciences in a research report on Friday, March 20th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $16.09.

Solid Biosciences Stock Up 8.2%

Shares of NASDAQ:SLDB opened at $7.23 on Wednesday. Solid Biosciences has a fifty-two week low of $2.41 and a fifty-two week high of $8.72. The firm’s 50 day moving average price is $6.53 and its 200 day moving average price is $5.82. The stock has a market cap of $563.29 million, a price-to-earnings ratio of -3.58 and a beta of 2.65.

Solid Biosciences (NASDAQ:SLDB) last posted its quarterly earnings results on Thursday, March 19th. The company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.01. On average, equities analysts anticipate that Solid Biosciences will post -2.84 EPS for the current year.

Insider Buying and Selling at Solid Biosciences

In related news, insider Gabriel Brooks sold 12,616 shares of the business’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total value of $81,247.04. Following the completion of the sale, the insider directly owned 84,092 shares of the company’s stock, valued at $541,552.48. The trade was a 13.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ilan Ganot sold 7,205 shares of the company’s stock in a transaction on Wednesday, February 4th. The shares were sold at an average price of $6.44, for a total transaction of $46,400.20. Following the completion of the transaction, the director owned 25,271 shares of the company’s stock, valued at $162,745.24. This represents a 22.19% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 597,672 shares of company stock worth $3,816,546. 1.90% of the stock is owned by insiders.

Institutional Trading of Solid Biosciences

A number of hedge funds and other institutional investors have recently made changes to their positions in SLDB. Invesco Ltd. lifted its holdings in shares of Solid Biosciences by 29.6% in the 4th quarter. Invesco Ltd. now owns 152,126 shares of the company’s stock valued at $858,000 after purchasing an additional 34,758 shares during the last quarter. XTX Topco Ltd purchased a new position in Solid Biosciences during the 4th quarter worth approximately $201,000. Vestal Point Capital LP increased its position in Solid Biosciences by 95.5% during the fourth quarter. Vestal Point Capital LP now owns 5,815,000 shares of the company’s stock worth $32,797,000 after buying an additional 2,840,000 shares during the period. Armistice Capital LLC increased its position in Solid Biosciences by 179.1% during the fourth quarter. Armistice Capital LLC now owns 2,612,000 shares of the company’s stock worth $14,732,000 after buying an additional 1,676,000 shares during the period. Finally, Schonfeld Strategic Advisors LLC lifted its stake in Solid Biosciences by 168.9% in the fourth quarter. Schonfeld Strategic Advisors LLC now owns 182,869 shares of the company’s stock valued at $1,031,000 after buying an additional 114,867 shares during the last quarter. Institutional investors and hedge funds own 81.46% of the company’s stock.

Solid Biosciences News Roundup

Here are the key news stories impacting Solid Biosciences this week:

• Positive Sentiment: JPMorgan raised its price target on SLDB to $12.00 from $11.00 and moved the stock to an “Overweight” stance — implying roughly a 66% upside from the referenced $7.23 level. This upgrade signals increased conviction from a large Wall Street shop and likely contributed to buying interest. Benzinga
• Positive Sentiment: HC Wainwright reiterated a “Buy” and lifted near-term EPS forecasts across multiple quarters and fiscal years (Q1–Q4 2026 and FY2026) while maintaining a $20 price target. They also issued later-year upside (FY2029–FY2030 projected profitability), trimming FY2026 losses significantly vs. prior forecasts — an analyst view that supports a more constructive growth/profitability outlook. Solid Biosciences Earns Buy Rating from HC Wainwright
• Neutral Sentiment: Reported short-interest data for March appears anomalous (shows 0 shares and NaN changes). Because the figures are likely erroneous or incomplete, they provide no clear signal about potential short-squeeze dynamics or bearish positioning at this time.

About Solid Biosciences

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.